Showing results (1-10 of 9) with videos related to
Sort By:
Pageof 1
Trends in Genetics : TIG|April 25, 2003
Transcriptional abnormalities in Huntington diseaseKatharine L Sugars, David C RubinszteinNucleic Acids Research|November 20, 2001
A minimal Bcl-x promoter is activated by Brn-3a and repressed by p53K L Sugars, V Budhram-Mahadeo, G Packham, et al.Journal of the American Podiatric Medical Association|October 1, 1994
Comparison of three methods for obtaining plantar pressures in nonpathologic subjectsB Meyers-Rice, L Sugars, T McPoil, et al.The Prostate|January 1, 1993
p53 oncogene mutations in three human prostate cancer cell linesA G Carroll, H J Voeller, L Sugars, et al.The Journal of Biological Chemistry|July 5, 2002
Glycogen synthase kinase-3beta inhibitors prevent cellular polyglutamine toxicity caused by the Huntington's disease mutationJenny Carmichael, Katherine L Sugars, Yi Ping Bao, et al.The Journal of Biological Chemistry|November 25, 2003
Decreased cAMP response element-mediated transcription: an early event in exon 1 and full-length cell models of Huntington's disease that contributes to polyglutamine pathogenesisKatharine L Sugars, Rosemary Brown, Lynnette J Cook, et al.Journal of Immunology (Baltimore, Md. : 1950)|March 8, 2000
TNF-alpha, IL-4, and IFN-gamma regulate differential expression of P- and E-selectin expression by porcine aortic endothelial cellsC J Stocker, K L Sugars, O A Harari, et al.Transplantation|September 6, 2000
Cloning of porcine intercellular adhesion molecule-1 and characterization of its induction on endothelial cells by cytokinesC J Stocker, K L Sugars, H Yarwood, et al.The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|November 19, 2004
Chemotherapy for the brain: the antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington's diseaseRobert J Ferrante, Hoon Ryu, James K Kubilus, et al.Pageof 1